Wingor Biotech possesses four major technology platforms: stem cells, immune cells, winEx™ exosomes, and "genetic engineering+". Its R&D team boasts over 50% of its members holding master's or doctoral degrees. Through continuous core technology innovation, the company has achieved breakthroughs in multiple therapeutic areas, including neurological and degenerative diseases, accumulating over 70 patent applications, including the only domestic patent for breast milk stem cells. It has led or participated in the formulation of six industry and national standards, continuously promoting the standardized development of the industry. Wingor Biotech's core product, "umbilical cord mesenchymal stem cells," has passed authoritative certification from the China National Institutes for Food and Drug Control. Ten of its products have been recognized as provincial-level high-tech products. The company has undertaken key national projects during the 14th Five-Year Plan period, achieving over 30 scientific and technological achievements and winning provincial science and technology awards. Its R&D and product quality system is highly recognized in the industry. Wingor Biotech has established nearly ten branches and regional cell preparation centers across multiple regions in China, forming a nationwide R&D, preparation, and service network.

Headquartered in Guangming Science City, Shenzhen, the company has established the South China Comprehensive Cell Bank, the South China Regional Cell Preparation Center, and the South China Biotechnology Innovation and Application Service Platform, all registered with the government, providing solid support for the clinical translation and industrialization of cell and gene therapy.